Prog Neuropsychopharmacol Biol Psychiatry 21, 69-102, (1997) Maurice, T., & Lockhart, B. P. View abstract in PubMed Post navigationPreviousPrevious post:Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain.NextNext post:SA4503, a novel cognitive enhancer with sigma1receptor agonist properties, facilitates NMDA receptor-dependent learning in mice.Related PostsAnavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s DiseaseJuly 29, 2021Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease DementiaJune 28, 2021Anavex Life Sciences Announces Closing of $50 Million Registered Direct OfferingJune 24, 2021Anavex Life Sciences Announces $50 Million Registered Direct OfferingJune 22, 2021
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s DiseaseJuly 29, 2021
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease DementiaJune 28, 2021
